tradingkey.logo

Penumbra Inc

PEN
View Detailed Chart

264.242USD

-8.488-3.11%
Market hours ETQuotes delayed by 15 min
10.30BMarket Cap
69.72P/E TTM

Penumbra Inc

264.242

-8.488-3.11%
Intraday
1m
30m
1h
D
W
M
D

Today

-3.11%

5 Days

-6.12%

1 Month

+4.36%

6 Months

-3.07%

Year to Date

+11.27%

1 Year

+41.35%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-12

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
11 / 207
Overall Ranking
99 / 4724
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 20 analysts
Buy
Current Rating
312.588
Target Price
+14.61%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 41.02% year-on-year.
Undervalued
The company’s latest PE is 71.48, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 37.32M shares, decreasing 7.06% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 3.85M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Ticker SymbolPEN
CompanyPenumbra Inc
CEOMr. Adam Elsesser, J.D.
Websitehttps://www.penumbrainc.com/
KeyAI